Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion
23 avr. 2020 12h30 HE
|
Deinove
Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion. Clinical tests have confirmed its ability to boost...
Commercial launch of BIOME Oléoactif®, new cosmetic active co-developed by Deinove and Hallstar France
18 mars 2020 13h30 HE
|
Deinove
BIOME Oléoactif® is an exclusive active ingredient that regulates skin microbiota and reinforces skin barrier function, thanks to a unique composition of innovative active molecules.This...
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance
11 mars 2020 13h00 HE
|
Deinove
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...
DEINOVE étoffe sa gamme commerciale d’ingrédientscosmétiques
19 févr. 2020 12h30 HE
|
Deinove
DEINOVE étoffe sa gamme commerciale d’ingrédients cosmétiques Son deuxième caroténoïde innovant présente notamment la particularité d’absorber la lumière bleue, responsable du vieillissement...
DEINOVE expands its range of cosmetic active ingredients
19 févr. 2020 12h30 HE
|
Deinove
DEINOVE expands its range of cosmetic active ingredients Its second innovative carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance...
Sharon Laboratories capitalizes on Deinove to sustain its development activities
06 févr. 2020 01h00 HE
|
Deinove
Sharon Laboratories capitalizes on Deinove to sustain its development activities The signed Memorandum of Understanding (MoU) covers the development and marketing of an exclusive range of bio-based...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
27 janv. 2020 01h30 HE
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
New industrial-scale production of Phyt-N-Resist® to supply the market
22 janv. 2020 12h30 HE
|
Deinove
New industrial-scale production of Phyt-N-Resist® to supply the market DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future...
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop
09 déc. 2019 12h30 HE
|
Deinove
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la...
DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology
09 déc. 2019 12h30 HE
|
Deinove
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la...